Vistagen Therapeutics (Nasdaq: VTGN) reported that its PALISADE-4 Phase III trial of fasedienol for social anxiety disorder failed to meet its primary endpoint, delivering a second consecutive Phase III miss for the intranasal pherine candidate and raising serious questions about whether the acute treatment model the company has pursued can generate registrational evidence in an unselected patient population. The result intensifies pressure on Vistagen to negotiate a credible path forward with the US FDA — one that depends heavily on a post-hoc subgroup signal and the evidentiary weight regulators are willing to assign to data from earlier, positive trials.
In the overall PALISADE-4 trial population of 238 adults with social anxiety disorder, fasedienol produced a least squares mean change from baseline on the Subjective Units of Distress Scale of -9.5 versus -11.4 for placebo, a difference of 1.9 points that was not statistically significant (p 0.427). Secondary endpoints showed no treatment difference. The trial was a randomized, double-blind, placebo-controlled Phase III study evaluating a single intranasal dose of fasedienol during a simulated public speaking challenge — a design that has now failed twice, following the December 2025 PALISADE-3 miss in which the drug produced a SUDS change of 13.6 versus 14.0 for placebo.
The placebo response in PALISADE-4 is notable. In a trial designed around acute, provoked anxiety, placebo-treated patients reported meaningful anxiety reduction during the public speaking challenge, compressing the window in which an active drug can demonstrate separation. This is a well-documented methodological challenge in anxiety pharmacology research: challenge paradigms that reliably provoke distress in clinical settings can also amplify non-specific effects, making the SUDS endpoint — a subjective, real-time self-report measure — particularly susceptible to regression to the mean and expectation effects.
Vistagen did report a nominally statistically significant signal in a post-hoc analysis restricted to patients with very severe social anxiety disorder, defined by a baseline Liebowitz Social Anxiety Scale score of 95 or greater. In this subpopulation of 123 patients — from which data from one disqualified site and a small number of subjects with ceiling or placebo run-in effects were excluded — fasedienol produced a SUDS change of -12.8 versus -3.7 for placebo, a difference of -9.1 points (p 0.036). The company described this as encouraging, and it is the most clinically interpretable signal to emerge from the PALISADE program's acute treatment arm.
The limitations of this finding, however, are significant. Post-hoc subgroup analyses are hypothesis-generating, not confirmatory. The subpopulation was defined after trial completion, the exclusions applied before analysis introduce additional analytical complexity, and the p-value of 0.036 would be interpreted cautiously because the analysis was post hoc and not adjusted for multiplicity. Regulators and the clinical community will scrutinize these data accordingly.
Vistagen's response to the PALISADE-4 result is a strategic pivot rather than a program termination. The company plans to meet with the US FDA to discuss a registrational pathway centered on the Liebowitz Social Anxiety Scale as the primary endpoint — consistent with how previously approved social anxiety disorder drugs, including GSK's Paxil (paroxetine) and Pfizer's Zoloft (sertraline) and Effexor XR (venlafaxine extended-release), established their efficacy — and a multi-dose rather than single-dose treatment model. The company indicated it would seek to use the positive PALISADE-2 Phase III trial and other placebo-controlled data from the PALISADE program as confirmatory evidence, invoking a June 2026 US FDA draft guidance on demonstrating substantial evidence of effectiveness.